KRAS and cancer: This is concordant with the fendiline-led inhibition of the KRASG12V-dependent MAPK signaling, compromised the proliferation the mutant KRAS-transformed cancer cells, as well as decreased the sizes of mutant KRAS-dependent tumors in xenograft models [55,57,58].